Corcept Therapeutics
CORT
NZ$120.10
Share price
-1.87%
Change (1 day)
125.60%
Change (1 year)
Categories
Corcept Therapeutics (CORT) - Total liabilities
Total liabilities on the balance sheet as of March 2025 : NZ$0.27 Billion
According to Corcept Therapeutics 's latest financial reports the company's total liabilities are NZ$0.27 Billion. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Corcept Therapeutics - Total liabilities on balance sheet (from 2003 to 2025)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2024-12-31 | NZ$0.28 B | 57.21% |
| 2023-12-31 | NZ$0.18 B | 41.28% |
| 2022-12-31 | NZ$0.12 B | 83.05% |
| 2021-12-31 | NZ$70.2 M | 4.67% |
| 2020-12-31 | NZ$67.06 M | 9.82% |
| 2019-12-31 | NZ$61.07 M | 14.39% |
| 2018-12-31 | NZ$53.38 M | 28.23% |
| 2017-12-31 | NZ$41.63 M | 5.35% |
| 2016-12-31 | NZ$39.51 M | -19.03% |
| 2015-12-31 | NZ$48.8 M | 0.59% |
| 2014-12-31 | NZ$48.52 M | -5.2% |
| 2013-12-31 | NZ$51.18 M | 12.61% |
| 2012-12-31 | NZ$45.45 M | 605.77% |
| 2011-12-31 | NZ$6.43 M | 28.71% |
| 2010-12-31 | NZ$5 M | 50.23% |
| 2009-12-31 | NZ$3.33 M | -32.61% |
| 2008-12-31 | NZ$4.94 M | 25.77% |
| 2007-12-31 | NZ$3.92 M | -21.84% |
| 2006-12-31 | NZ$5.02 M | -3.55% |
| 2005-12-31 | NZ$5.21 M | 103.93% |
| 2004-12-31 | NZ$2.55 M | -96.16% |
| 2003-12-31 | NZ$66.53 M | -20.38% |
| 2002-12-31 | NZ$83.56 M | 1741.9% |
| 2001-12-31 | NZ$4.53 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | NZ$194.35 B | 70,723.07% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | NZ$126.09 B | 45,851.46% | 🇺🇸 USA |
 Novartis NVS | NZ$103.41 B | 37,584.01% | 🇨🇭 Switzerland |
 Eli Lilly LLY | NZ$123.68 B | 44,970.79% | 🇺🇸 USA |
 Pfizer PFE | NZ$197.42 B | 71,843.98% | 🇺🇸 USA |
 Merck MRK | NZ$112.21 B | 40,791.10% | 🇺🇸 USA |
 Esperion Therapeutics ESPR | NZ$1.26 B | 359.79% | 🇺🇸 USA |
 MannKind Corp MNKD | NZ$0.78 B | 187.28% | 🇺🇸 USA |
 BioMarin Pharmaceutical BMRN | NZ$2.27 B | 729.53% | 🇺🇸 USA |